TNFRSF4 and neoplasm: Novel therapies targeting inhibitory (e.g., IDO-1, LAG-3, TIGIT, TIM-3, VISTA) and stimulatory (e.g., ICOS, GITR, OX40, 4-IBB) proteins within the tumor microenvironment (TME) are under active investigation (3–7).